During the last session, Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares were 1.04 million, with the beta value of the company hitting 2.29. At the end of the trading day, the stock’s price was $1.63, reflecting an intraday gain of 7.24% or $0.11. The 52-week high for the ITRM share is $2.50, that puts it down -53.37 from that peak though still a striking 50.31% gain since the share price plummeted to a 52-week low of $0.81. The company’s market capitalization is $44.85M, and the average intraday trading volume over the past 10 days was 1.04 million shares, and the average trade volume was 2.43 million shares over the past three months.
Iterum Therapeutics Plc (ITRM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ITRM has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Iterum Therapeutics Plc (ITRM) registered a 7.24% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.24% in intraday trading to $1.63, hitting a weekly high. The stock’s 5-day price performance is 13.99%, and it has moved by 50.93% in 30 days. Based on these gigs, the overall price performance for the year is 1.24%. The short interest in Iterum Therapeutics Plc (NASDAQ:ITRM) is 2.53 million shares and it means that shorts have 0.46 day(s) to cover.
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Statistics show that Iterum Therapeutics Plc has outperformed its competitors in share price, compared to the industry in which it operates. Iterum Therapeutics Plc (ITRM) shares have gone up 15.60% during the last six months, with a year-to-date growth rate more than the industry average at 59.80% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 70.37% this quarter and then jump 39.47% in the quarter after that.
Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 1.34M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.62%. While earnings are projected to return 65.38% in 2024.
ITRM Dividends
Iterum Therapeutics Plc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
Iterum Therapeutics Plc insiders own 1.81% of total outstanding shares while institutional holders control 8.99%, with the float percentage being 9.15%. BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC is the largest shareholder of the company, while 19.0 institutions own stock in it. As of 2024-06-30, the company held over 66.0 shares (or 0.0004% of all shares), a total value of $76.0 in shares.
